A jury has ordered Bayer to pay $2 billion after a lawsuit claiming Roundup causes cancer. A couple sued the company, saying they were diagnosed with cancer after using the weedkiller made by Monsanto, which was acquired by Bayer last year. The jury said the product did not properly warn of its cancer risk. (CNBC)
Scientists have predicted the next measles outbreaks will be in Chicago, Los Angeles and Miami. The study mapped the 25 counties most at risk of measles because of their vaccine-exemption rates and proximity to airports. (New York Times)
AbbVie has settled its latest Humira patent lawsuit. The settlement will allow Boehringer Ingelheim to sell a biosimilar version of the medicine, but not until July 2023. Boehringer Ingelheim was the last in a series of drugmakers that made similar deals with AbbVie. (STAT)
Philadelphia’s soda tax has led to decreased sales, as well as unclear health benefits. Research found that sales of soda dropped 38% in 2017, but sales of non-taxed drinks didn’t increase during the study period. Advocates said it is a promising sign. (Associated Press)
Myovant Sciences’ uterine fibroid drug succeeded in a late-stage study. The report tested the efficacy of Myovant’s Relugolix and two hormone therapies. There are currently few treatments for uterine fibroids. (Reuters)
